Stoke Therapeutics (STOK) Other Non Operating Income (2019 - 2026)
Stoke Therapeutics (STOK) recorded quarterly Other Non Operating Income of $18000.0 in Q1 2026, up 116.36% quarter-over-quarter from -$110000.0 in Q4 2025, and down 35.71% on a YoY basis from $28000.0 in Q1 2025.
Stoke Therapeutics (STOK) Other Non Operating Income (2019 - 2026) Analysis & Trends
Stoke Therapeutics' Other Non Operating Income history runs 8 years deep, the most recent figure standing at $18000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 35.71% year-over-year to $18000.0; the TTM figure through Mar 2026 stood at -$61000.0 (down 129.19% YoY), while the FY2025 annual figure was -$51000.0, up 79.35% from the prior year.
- Other Non Operating Income was $18000.0 for Q1 2026 at Stoke Therapeutics, up from -$110000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $201000.0 in Q4 2024 to a low of -$428000.0 in Q1 2024.
- Historically, Other Non Operating Income has averaged $3117.6 across 5 years, with a median of $41000.0 in 2023.
- Biggest YoY gain for Other Non Operating Income was 390.24% in 2024; the steepest drop was 1119.05% in 2024.
- A 5-year view of Other Non Operating Income shows it stood at $42000.0 in 2022, then fell by 2.38% to $41000.0 in 2023, then jumped by 390.24% to $201000.0 in 2024, then slumped by 154.73% to -$110000.0 in 2025, then surged by 116.36% to $18000.0 in 2026.
- The last three Other Non Operating Income figures came in at $18000.0 (Q1 2026), -$110000.0 (Q4 2025), and $3000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | -110,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 28,000.00 |
| Mar 31, 2025 | 28,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | -48,000.00 |
| Mar 31, 2024 | -428,000.00 |
| Dec 31, 2023 | 41,000.00 |
| Sep 30, 2023 | 41,000.00 |
| Jun 30, 2023 | 41,000.00 |
| Mar 31, 2023 | 42,000.00 |
| Dec 31, 2022 | 42,000.00 |
| Sep 30, 2022 | 42,000.00 |
| Jun 30, 2022 | 42,000.00 |
| Mar 31, 2022 | 42,000.00 |
| Dec 31, 2021 | 42,000.00 |
| Sep 30, 2021 | 42,000.00 |
| Jun 30, 2021 | 28,000.00 |